Anixa is focused on harnessing the bodyâs immune system in the fight against cancer. Anixaâs therapeutics portfolio includes a cancer immunotherapy program, which uses chimeric endocrine receptor t-cell (CER-T) technology, a novel type of CAR-T, and a cancer vaccine technology focused specifically on triple negative breast cancer (TNBC), the most lethal form of the disease. Anixaâs diagnostics portfolio includes the CchekTM liquid biopsy technology, a series of inexpensive non-invasive blood tests for early detection of solid tumors based on the bodyâs immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Source
No articles found.
EyeGate is developing and commercializing products for treating diseases and disor...
EyeGate is developing and commercializing produ...
The mission of Cassava Sciences is to detect and treat neurodegenerative diseases,...
The mission of Cassava Sciences is to detect an...
Genmab is a publicly traded, international biotechnology company specializing in t...
Genmab is a publicly traded, international biot...
BioHealthonomics Inc. is a research and development biotechnology & healthcare com...
BioHealthonomics Inc. is a research and develop...
Join the National Investor Network and get the latest information with your interests in mind.